PRL and polycystic ovary syndrome: The drug decreased circulating prolactin levels independently of the reason for prolactin excess: in microprolactinomas [2], iatrogenic hyperprolactinemia [3,4,5], empty sella syndrome [2], traumatic brain injury [2] and polycystic ovary syndrome [6], and in all these conditions the degree of reduction in prolactin levels correlated with baseline hormone levels.